Select adult patients and pediatric patients 8 years of age and older for TZIELD treatment who have a diagnosis of Stage 2 type 1 diabetes.
The first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D)
in adult and pediatric patients aged 8 years and older with Stage 2 T1D.1 See patient selection criteria.
Most common adverse reactions (>10%) were lymphopenia, rash, leukopenia, and headache.
Please see full Prescribing Information, including patient selection criteria, and Medication Guide.
View Important Safety Information page.